<DOC>
	<DOCNO>NCT00688077</DOCNO>
	<brief_summary>Introduction : Based experience calcitonin FGF-23 suppressive agent patient FGF-23 produce tumor hypothesize calcitonin may physiologically important regulator FGF-23 production secretion healthy human . Aim : In study wish examine FGF-23 suppressive effect calcitonin healthy men . Study Design : placebo-controlled , cross-over study Method : - All twelve subject examine two occasion , exposure placebo 1 ml NaCl 0.9 % subcutaneously , follow calcitonin 200 IU/ml subcutaneously - On occasion frequent bloodsampling take place , indwell catheter de forearm vein . - Sampling time : -15 , 0 , 60 , 120 , 240 , 360 , 480 minute - Mealtimes : Calcium Phosphate intake standardize occasion - All sample analyze FGF-23 , use C-terminal FGF-23 ELISA kit ( Immunotopics , San Clemente , USA ) measure intact C-terminal fragment FGF-23 , one measure intact FGF-23 - Samples obtain T-15 , T0 , T240 T480 store later analysis Ca , albumin , PO4 , PTH , 25-OHD 1,25-OHD Endpoint : A change 25 % de serum FGF-23 level response single subcutaneous injection calcitonin 200 IU .</brief_summary>
	<brief_title>FGF-23 Suppressibility Calcitonin</brief_title>
	<detailed_description />
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Healthy man , 2055 year old , BMI 2027 kg/m2 . Serum creatinin &gt; 100 mmol/L , glomerular filtration rate &lt; 80 ml/min . Abnormal serum Ca , PO4 , albumin , 25OH vitamin D , PTH level . Any medication .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Fibroblast growth factor - 23</keyword>
	<keyword>Calcitonin</keyword>
</DOC>